secwatch.observer — SEC 8-K summary
======================================

Issuer:     Abpro Holdings, Inc. (ABPO)
CIK:        0001893219
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001213900-26-001570
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abpro and Celltrion announce FDA IND clearance for lead multispecific antibody ABP-102 / CT-P72
--------------------------------------------------------------------------------

- FDA cleared IND for ABP-102 / CT-P72, a multispecific HER2 × CD3 T-cell engager targeting HER2-positive solid tumors.
- Phase 1 clinical trial anticipated to commence in H1 2026, led by Celltrion under co-development collaboration.
- Preclinical data showed selective antitumor activity in HER2-high models and was well tolerated in NHP studies up to 80 mg/kg.
- Candidate designed to enhance tumor selectivity and limit activity in HER2-low tissues, aiming to reduce cytokine release syndrome risk.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1893219/000121390026001570/0001213900-26-001570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1893219/000121390026001570/ea0271844-8k_abpro.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-001570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer